Αποτελέσματα Αναζήτησης
Exanta FDA Approval Status. FDA Approved: No. Brand name: Exanta. Generic name: ximelagatran. Company: AstraZeneca. Treatment for: Prevention of Thromboembolism in Atrial Fibrillation.
approval for the use of EXANTA® (ximelagatran) Tablets as: œ An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention of venous thromboembolism (VTE) after standard treatment for an episode of acute
New Drug Application (NDA) 21-686, submitted by AstraZeneca LP (AstraZeneca), requests approval for the use of EXANTA® (ximelagatran) Tablets as: An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention of venous thromboembolism (VTE) after standard treatment for an episode of acute VTE An oral 36-mg bid fixed dose ...
Ximelagatran was generally well tolerated in the trial populations, but a small proportion (5–6%) developed elevated liver enzyme levels, which prompted the FDA to reject an initial application for approval in 2004. The further development was discontinued in 2006 following reports of hepatotoxicity. Subsequent analysis of Phase 2 clinical ...
2 ημέρες πριν · Typical Dosing. Both weight loss medications are given as weekly injectable doses, but their dosage amounts differ. Semaglutide typically begins with a 0.25 mg weekly dose that slowly increases and can reach up to 2.4 mg per week. As for tirzepatide, it generally starts at 2.5 mg per week and gradually increases up to 15 mg per week.
25 Ιουν 2003 · Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI) under development by AstraZeneca. As the first fixed-dose, oral anticoagulant to be approved since the introduction of warfarin over 50 years ago, it was seen as an important new treatment for the prevention and treatment of Venous Thromboembolism (VTE) and potentially for stroke ...
AstraZeneca announced that it has submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) seeking marketing clearance for its investigational oral direct thrombin inhibitor Exanta (ximelagatran) for the prevention of venous thromboembolism (VTE) in patients undergoing knee-replacement surgery; for the prevention of ...
